Marshall Wace LLP Takes $671,000 Position in CorVel Co. (NASDAQ:CRVL)

Marshall Wace LLP acquired a new position in CorVel Co. (NASDAQ:CRVL - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,035 shares of the business services provider's stock, valued at approximately $671,000.

Other institutional investors have also added to or reduced their stakes in the company. Jump Financial LLC grew its holdings in shares of CorVel by 219.2% in the fourth quarter. Jump Financial LLC now owns 9,987 shares of the business services provider's stock worth $1,111,000 after purchasing an additional 6,858 shares during the last quarter. Walleye Capital LLC bought a new position in CorVel in the 4th quarter worth about $730,000. Mariner LLC grew its stake in CorVel by 214.3% in the 4th quarter. Mariner LLC now owns 2,637 shares of the business services provider's stock worth $293,000 after acquiring an additional 1,798 shares in the last quarter. Barclays PLC increased its position in shares of CorVel by 209.3% during the fourth quarter. Barclays PLC now owns 49,409 shares of the business services provider's stock worth $5,497,000 after acquiring an additional 33,432 shares during the period. Finally, Summit Investment Advisors Inc. raised its stake in shares of CorVel by 221.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 2,784 shares of the business services provider's stock valued at $310,000 after acquiring an additional 1,917 shares in the last quarter. Institutional investors own 51.36% of the company's stock.

Insider Activity

In other news, Director Jeffrey J. Michael sold 10,477 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $116.45, for a total transaction of $1,220,046.65. Following the completion of the sale, the director now owns 568,310 shares in the company, valued at approximately $66,179,699.50. This represents a 1.81 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Steven J. Hamerslag sold 10,000 shares of the business's stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $123.48, for a total value of $1,234,800.00. Following the transaction, the director now owns 314,000 shares in the company, valued at approximately $38,772,720. This trade represents a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 48,723 shares of company stock worth $5,757,140. 47.57% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Separately, StockNews.com upgraded CorVel from a "hold" rating to a "buy" rating in a report on Friday, April 18th.

CorVel Stock Performance

CorVel stock traded down $1.51 during midday trading on Monday, hitting $110.52. 127,993 shares of the company's stock were exchanged, compared to its average volume of 119,445. The company has a market cap of $5.68 billion, a PE ratio of 65.01 and a beta of 0.94. The firm has a 50-day moving average of $110.38 and a two-hundred day moving average of $115.84. CorVel Co. has a 12 month low of $76.53 and a 12 month high of $128.61.

CorVel (NASDAQ:CRVL - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The business services provider reported $0.46 earnings per share (EPS) for the quarter. CorVel had a net margin of 10.12% and a return on equity of 32.22%.

CorVel Profile

CorVel Corporation provides workers' compensation, auto, liability, and health solutions. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company also offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement, retrospective utilization review, facility claim review, professional review, pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services, as well as Medicare solutions.